Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
Provided By GlobeNewswire
Last update: May 12, 2025
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study
Read more at globenewswire.com
